Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): Benev - Consultant, Luvo Consultant,

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): L'Oréal

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
Yes
Please specify date...: Disclosed
and status : march 10 2023

This work is presented thanks to the support of: L'Oréal

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): regenX, galderma

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): regenX, galderma

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: regenX, galderma

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): Morphiya biotech

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
Yes
Please specify date...: aprroved
and status : hybrid exosomes

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: 1. Explain exosomes and hybrasomes
2. Present results in human clinical trials
3. Make recommendations for optimal clinical applications

Introduction: Exosomes contain various growth factors, proteins, and genetic material that may contribute to tissue regeneration. This regenerative potential is of interest in plastic surgery for promoting wound healing, reducing scarring, and enhancing tissue repair. In addition to tissue regeneration, exosomes play a role in stem cell activation, possess anti-inflammatory properties, stimulate collagen production, enhance fat transfer and minimize scarring. They can be delivered topically or via minimally invasive methods as a non-surgical option for tissue regeneration.

Materials / method: To create a product that can be registered and used as a cosmeceutical, a unique technique was employed to develop a bovine umbilical cord tissue product hybridized with a liposomal agent. This new product is called a hybrasome and has now been tested in 100’s of patients by independent dermatology research companies. The product was compared to 0.02% retinol as well as to a leading consumer brand, Augustine Bader in a split face study. In addition, we have now used the product in 50 patients with outstanding feedback.

Results: The results have shown that the hybrasome cream significantly outperforms both Retinol as well as Augustine Bader. Results of these studies will be presented in detail. There have been virtually no side effects.

Conclusion: Hybrasome creams represent a new paradigm in the use of subcellular particles such as exosomes. Advantages include, FDA registration, the “youthful” messages of cord tissue exosomes” and there prolonged shelf life. Compared to both retinol as well as a leading consumer brand, hybrasomes were markedly better in virtually all categories of skin aging.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): Mage Group

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: This abstract discusses the potential benefits of exosomes as an adjuvant therapy with standard first-line energy-based treatments for severe acne scar remodeling. Atrophic acne scars with severe underlying fibrosis can be very challenging to treat, especially in the forehead, and temple areas, and is even harder in darker skin types. Exosomes, are small lipid bi-layered nanovesicles with rich in growth factors, nucleotides, proteins, and lipids that have shown promising improvement in wound healing, scar remodeling can offer synergistic benefits in the optimal correction of acne scars.

Introduction: Acne scars are the most common troublesome chronic inflammatory skin condition that leads to scarring and hyperpigmentation. Post-acne sequelae can have a significant impact on a person's self-esteem and quality of life. While traditional treatments such as peels, microdermabrasion, dermabrasion, subcision, laser therapy, and RF micro needling have shown some success in improving the appearance of acne scars, there is a growing interest in the use of exosomes as adjuvant therapy for these treatments. Exosomes offer excellent anti-inflammatory benefits in the treatment of acne scar revision.

Materials / method: We reviewed acne scar patients who received exosome and EBD combo therapy for 3 years from 2020 to 2023. These patients had all types of acne scars with various stages, depth, fibrosis, with or without erythema and hyperpigmentation. This was a 3 step procedure. All of them had subcision for atrophic rolling acne scars,followed by FRF or 1550 or both then had topical application of exosomes.

Results: Our patients noticed a visible improvement in the quality of skin after two sessions of exosomes combo treatment with EBD and subcision.They had a significant reduction of acne-induced erythema, and acne-induced hyperpigmentation without the use of vascular lasers or PICO lasers. My patients reported high levels of satisfaction with the brightening effect and smoothness with fewer sessions. Almost all of them had shorter recovery time, no side effects such as post laser PIE and PIH.

Conclusion: Exosomes offer a powerful anti-inflammatory & regenerative benefit that can synergistically work with energy-based treatments in patients with difficult or severe acne scarring. The exosomes reducing chronic inflammation, their effect on all 4 phases of wound healing, and reduction of erythema and pigmentation can be great adjuvant therapy for both the prevention and treatment of acne scars. The cell-free Exosomes adjuvant therapy with EBDs can further benefit in preventing and treating acne scars, especially in high-risk SOC patients and severe acne scars with erythema and pigmentation.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): COSMEDICIAN COMPANY

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability